Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: A module and system are provided for reducing or suppressing ringing occurring in a digital signal to be transmitted. A transmission module Ma includes a transmitter 200a configured to transmit a digital signal, a transmission antenna 100a constituted by a metal plate, or by a conductor formed on an insulator, the transmission antenna 100a being configured to be electromagnetically or magnetically coupled to a reception antenna 100b of a non-contact reception module Mb for digital communication, and a resistor 400a connected in series between the transmitter 200a and the transmission antenna 100a. The resistor 400a has such a resistance value that the resistor 400a entirely blunts a waveform of the digital signal outputted from the transmitter 200a so as to reduce or suppress ringing occurring in the digital signal. The blunted digital signal is to be inputted into the transmission antenna 100a.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: A sleep determination apparatus includes a heart rate data obtainer that obtains, based on data regarding a heart rate of a body of a user, a very low frequency component (VLF), a ratio of a low frequency component (LF) to a high frequency component (HF), a mean heartbeat interval (RRI), and a standard deviation of each heartbeat interval (RRI) of the heart rate as heart rate variability parameters indicating a heart rate state; and a sleep state determiner that determines which of a plurality of sleep stages the user is in, using the heart rate variability parameters, in such a manner as to distinguish between a first non-REM sleep stage and a second non-REM sleep stage.

Abstract: A subject of the present invention is to provide an anti AQP3 antibody specifically recognizing the extracellular domain of aquaporin 3 (AQP3), which is one type of a water channel protein. By selecting a monoclonal antibody which specifically binds to an oligopeptide included in loop C as one of the extracellular domains of AQP3, an anti AQP3 antibody that is desired in the present invention is provided. An anti AQP3 monoclonal antibody of the present invention can directly bind, from the outside of a cell, to AQP3 present in a cell membrane. Furthermore, as an anti AQP3 monoclonal antibody of the present invention can have an inhibitory activity, the function of permeating a low molecular weight molecule or the like, which is carried by AQP3, can be suppressed.

Abstract: A cell preparation for treating brain tumors used in combination with a prodrug of a drug that kills, or inhibits proliferation of, tumor cells, wherein the cell preparation comprises neural stem cells derived from iPS cells or ES cells having a suicide gene, and the prodrug is a prodrug activated with an enzyme produced by expression of the suicide gene comprised in the neural stem cells is provided to solve the difficulty of obtaining neural stem cells, which is problematic, and to establish new means for treating brain tumors using neural stem cells.

Abstract: To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.

Abstract: To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.

Abstract: Ringing occurring in a digital signal to be transmitted, is reduced or suppressed. A transmission module Ma includes a transmitter 200a configured to transmit a digital signal, a transmission antenna 100a constituted by a metal plate, or by a conductor formed on an insulator. The transmission antenna 100a is configured to be electromagnetically or magnetically coupled to a reception antenna 100b of a non-contact reception module Mb for digital communication. A resistor 400a is connected in series between the transmitter 200a and the transmission antenna 100a. The resistor 400a has such a resistance value that the resistor 400a entirely blunts a waveform of the digital signal outputted from the transmitter 200a so as to reduce or suppress ringing occurring in the digital signal. The blunted digital signal can be inputted into the transmission antenna 100a.

Abstract: A haptic transmission system includes a master device and a slave device. The master device controls position and force in an operation of the master device based on information acquired from the operation of the master device and information relating to a response of the slave device, and compensates for a communication delay in a communication path with respect to the control of force. The slave device controls speed and force in an operation of the slave device based on information acquired from the operation of the slave device and information relating to control from the master device.

Abstract: Provided is a novel marker for determining anti-cancer agent sensitivity. The present invention provides a marker for determining sensitivity to an anti-cancer agent, the anti-cancer agent including irinotecan or SN-38 or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker comprising one or more molecules selected from the group consisting of 5A4CR, ALA, ASP, CYS, CSSG, GLC3P, HIS, ILE, LEU, LYS, METSF, N6TLY, N6ALY, OCTA, SER, TUCA, THR, TRP, TYR and VAL. The present invention also provides a marker for determining sensitivity to an anti-cancer agent, the anti-cancer agent including irinotecan or SN-38 or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker comprising one or more molecules selected from the group consisting of 3IND, 4OVAL, 5A4CR, ALA, BENZA, CREAT, CSSG, DECNA, GABB, GLC3P, HYPTA, LYS, METSF, N8ASR, QUINA, SARCO, TMNO and VAL.

Abstract: The present invention provides a liquid crystal display method capable of, when a screen thereof is observed through a polarizer such as sunglasses, ensuring an excellent visibility regardless of the angle of observation. In a liquid crystal display device at least having a backlight light source, a liquid crystal cell, and a polarizer disposed on a viewing side of the liquid crystal cell, a white light-emitting diode is used as the backlight light source; and a polymer film having a retardation of from 3,000 nm to 30,000 nm is used so as to be disposed on the viewing side of the polarizer so that an angle between an absorption axis of the polarizer and a slow axis of the polymer film becomes about 45 degrees.

Abstract: The aim of the present invention lies in inexpensively providing a thin-film laminated film having excellent barrier properties. A further aim of the present invention lies in providing a method for producing a thin-film laminated film in which a plurality of thin films are coated on a plastic film by means of atmospheric-pressure plasma CVD which has low equipment costs and running costs, and also in providing a thin-film laminated film production apparatus which is able to operate continuously for a long period of time and can produce high-speed coating. A thin film according to the present invention includes a plastic film, a first silicon oxide-based thin film containing silicon oxide as the main component, and a first amorphous carbon-based thin film. The first amorphous carbon-based thin film is formed on the first silicon oxide-based thin film. The first silicon oxide-based thin film has pinholes with a diameter in the range of 10-200 nm.

Abstract: An ultrasonic transducer (10) emits ultrasonic waves toward a culture solution (3) stored with cells (2) in a culture vessel (1). An acquirer acquires information indicating a settling state of the cells (2) in the culture solution (3). A controller controls an operation of the ultrasonic transducer (10) based on the information indicating the settling state of the cells (2).

Abstract: A method for extracting substances from a fecal sample using mass spectrometry or nuclear magnetic resonance spectrometry, and metagenomic analysis using a next-generation sequencer.

Abstract: Problems of the present invention is to provide a novel compound or a salt thereof capable of activating natural killer T cell, a natural killer T cell activating agent containing such a compound or a salt thereof, and a pharmaceutical composition. The compound of the present invention is a compound represented by the following formula (1) or a salt thereof. It is preferable that total carbon number of the number of carbon atoms in the monovalent hydrocarbon group in R1 in the formula (1) excluding a sustitutent and the number of carbon atoms in the divalent hydrocarbon group in X1 is 5 to 50. The natural killer T cell activating agent contains the aforementioned compound or a salt thereof. The pharmaceutical composition contains the aforementioned compound or a pharmacologically acceptable salt thereof.

Abstract: A method for producing a tau-related disease model is provided. The method includes three-dimensionally culturing pluripotent stem cells having a mutation in a Microtubule Associated. Protein Tau (MAPT) gene to form a nerve organoid, and dissociating the nerve organoid into single cells and performing two-dimensional adherent culture to obtain neurons, in which the neurons are a tau-related disease model.

Abstract: A high-frequency electrosurgical treatment instrument for operations, includes a pair of forceps pieces, an insulating member, a transmission member, a manipulation rod member, a distal end cover member, a shaft member and a manipulation portion. The instrument, includes a flow channel portion formed between the manipulation rod member and the shaft member, the flow channel portion being disposed along a longitudinal direction of the manipulation rod member to allow liquid to flow; a groove portion that communicates with the flow channel portion to allow the liquid to flow from the flow channel portion; and an opening portion that communicates with the groove portion to supply the liquid near the proximal end portions of the pair of forceps pieces.

Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.